Quantcast

Latest Neurofibrillary tangle Stories

2009-11-11 18:05:06

Protein reduces levels of amyloid beta and tau hyperphosphorylation, 2 hallmarks of Alzheimer's Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells. Amyloid beta is responsible for the plaques found in...

2009-11-11 17:52:19

A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). The research, published by Cell Press in the November 12 issue of the journal Neuron, finds that the novel gene interacts with a key cellular enzyme previously linked with AD pathology, thereby uncovering a new strategy for treating this devastating disorder. AD is an incurable neurodegenerative disease characterized by a...

2009-07-15 08:12:50

Immunotherapy targets Alzheimer's tau tangles and more doctors are diagnosing and treating mild cognitive impairmentNew insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins "“ beta amyloid and phosphorylated tau "“ that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.Scientists also reported on how clinicians view...

2009-07-15 01:30:00

VIENNA, July 15 /PRNewswire-USNewswire/ -- New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna. (Logo: http://www.newscom.com/cgi-bin/prnh/20090529/ICADLOGO ) Scientists also reported on how clinicians view and treat mild...

123464959aa2cc84ed9e6474920e234b1
2009-06-08 11:15:00

New research has shown that a rogue protein thought to cause Alzheimer's can spread through the brain, turning healthy tissue bad, BBC News reported.The tau protein may share characteristics with the prion proteins that cause vCJD. Scientists found it triggered formation of protein tangles linked to Alzheimer's after they injected it into the brains of healthy mice.But the study, published in the Nature Cell Biology, said this did not mean tau could be passed from person to person.Tau is a...

2009-05-05 08:53:43

Rare genetic disorder may benefit from development of new dementia treatments Researchers seeking to understand the causes of a rare genetic lysosomal storage disease, Sanfilippo syndrome type B, were surprised to find protein aggregates, known as neurofibrillary tangles, that are usually seen in Alzheimer's and other forms of dementia, according to a study published May 4 in the Proceedings of the National Academy of Sciences. The discovery, in a study conducted at the Los Angeles Biomedical...

2009-02-06 08:54:59

Scientists at UC Santa Barbara have discovered that a protein called BAG2 is important for understanding Alzheimer's disease and may open up new targets for drug discovery. They are ready to move from studying these proteins in culture to finding out how they work with mice.In a paper published this week in the Journal of Neuroscience, the scientists describe important activities of BAG2 in cleaning up brain cells. The protein tau is normally found in brain cells, but scientists don't know...

2008-08-08 09:00:28

ProteoTech has completed regulatory investigational new drug requirements and has received clearance from the FDA to initiate its Phase I human clinical trial on Exebryl-1, a small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. Initial studies suggest that Exebryl-1 may have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The...

2008-08-07 09:00:14

KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. ProteoTech initiated its Phase 1 human trial on July 29, 2008. At the 2008 International Conference on Alzheimer's...

2008-07-30 12:00:21

CHICAGO, ILLINOIS--(Marketwire - July 30, 2008) - Allon Therapeutics Inc. (TSX:NPC) - Clinical trial data presented today to two scientific workshops at the International Conference on Alzheimer's Disease and Related Disorders (ICAD 2008) validate the therapeutic potential of addressing the "tangles" component of the classic Alzheimer's "plaques and tangles" pathology. The data from a clinical trial evaluating drug candidate AL-108 in 144 patients with amnestic mild cognitive impairment...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related